Migraine

Certain acute treatments for episodic migraines improved pain and function, according to a systemic review and meta-analysis study published in JAMA.

Rebecca Erwin Wells, MD, MPH, received the Early Career Award at the American Headache Society Annual Scientific Meeting in recognition of her paper that examined the impact of migraine on “multiple domains of life.”

Cefaly Technology’s nerve stimulation device, when compared with sham stimulation, was more effective in delivering pain relief and freedom from most bothersome migraine symptom, phase 3 trial data show.

Atogepant demonstrated “clinically meaningful and statistically significant” improvement for the primary endpoint of decreasing the mean number of monthly migraine days compared with placebo, according to results of a phase 3 trial.

Treatment with 10 mg and 20 mg of intranasal zavegepant met the primary endpoints in a randomized clinical trial — freedom from pain and the most bothersome symptom after 2 hours.

Women with menstrual migraine who were treated with galcanezumab had fewer monthly migraine headache days compared with women who received placebo, according to an analysis of three phase 3 trials.

Self-reported migraine treatment records collected via a smartphone application provided insights into migraine triggers and medication effectiveness.

Patients with migraine who took calcitonin gene-related peptide-targeted monoclonal antibody therapy in combination with onabotulinumtoxinA had fewer monthly headache days and less migraine-related disability, according to researchers.

Updated analyses from the phase 3, open-label STOP 301 study of nasal dihydroergotamine-based INP104 for the treatment of migraine provides new safety and tolerability data regarding nausea as well as nasal and cardiovascular outcomes.

Fewer than 10% of patients with migraine overcome four obstacles “to good medical outcomes” according to results of the Chronic Migraine Epidemiology and Outcomes, or CaMEO, study.